Spero Therapeutics (SPRO)

• Market cap: $104M
• 1 day: -1.07%
• 5 days: -1.60%
• 1 month: -20.60%
• 3 months: 171.26%
• 6 months: 131.95%
• Year to date: 71.30%
• 1 year: 36.03%
• 5 years: -84.60%
• 10 years: -83.91%
• Sector: Healthcare
• Industry: Biotechnology

About: Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Employees: 32

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

194% more capital invested

Capital invested by funds: $10.9M [Q1] → $31.9M (+$21M) [Q2]

27% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 11

8% more funds holding

Funds holding: 39 [Q1] → 42 (+3) [Q2]

0% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 9

8.02% less ownership

Funds ownership: 27.71% [Q1] → 19.69% (-8.02%) [Q2]

64% less call options, than puts

Call options by funds: $447K | Put options by funds: $1.24M